Immunoglobulin therapy for plasma cell-rich rejection in the renal allograft.
Transplantation
; 82(4): 567-9, 2006 Aug 27.
Article
en En
| MEDLINE
| ID: mdl-16926602
ABSTRACT
Plasma cell-rich acute rejection (PCAR) is associated with poor allograft outcome in renal transplantation. Previous studies report a graft half-life of six months after a single PCAR episode. However, the management of this condition is unclear. Intravenous immunoglobulin (IVIG) therapy, by virtue of its immunomodulating properties, and its influence on B-cell maturation into plasma cells, may be a good candidate for reversing this type of rejection. We report four episodes of PCAR in two patients who responded well to IVIG with improvement in renal function.
Buscar en Google
Banco de datos:
MEDLINE
Asunto principal:
Células Plasmáticas
/
Trasplante de Riñón
/
Inmunoglobulinas Intravenosas
/
Rechazo de Injerto
Límite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Transplantation
Año:
2006
Tipo del documento:
Article
País de afiliación:
Estados Unidos